Compare NSSC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | VCEL |
|---|---|---|
| Founded | 1969 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | 1996 |
| Metric | NSSC | VCEL |
|---|---|---|
| Price | $37.33 | $34.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $48.17 | ★ $57.75 |
| AVG Volume (30 Days) | 364.5K | ★ 589.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.70 | N/A |
| Revenue | $181,621,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $13.63 | $19.40 |
| Revenue Next Year | $10.05 | $18.24 |
| P/E Ratio | $52.59 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $26.44 | $28.95 |
| 52 Week High | $47.61 | $45.97 |
| Indicator | NSSC | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 52.98 |
| Support Level | $29.88 | $33.91 |
| Resistance Level | $44.43 | $38.31 |
| Average True Range (ATR) | 1.48 | 1.87 |
| MACD | -0.38 | 0.07 |
| Stochastic Oscillator | 28.28 | 35.26 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.